In this special series of Translational Lung Cancer Research dedicated to ALK-positive NSCLC, our esteemed colleagues present a comprehensive up-to-date review of this field, covering not only the latest advances but also the ongoing challenges. We hope that the readers of Translational Lung Cancer Research will find the series informative and inspiring as we collectively provide care for patients with ALK-positive lung cancer and embark on collaborative research efforts to tackle the next frontier in transforming clinical outcomes.
Current opportunities and challenges in ALK-positive lung cancer
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review
Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease
Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
Patient-led advocacy in ALK-positive lung cancer
Disclosure:
The series “ALK-Positive NSCLC” was commissioned by the editorial office, Translational Lung Cancer Research without any funding or sponsorship. Justin F. Gainor and Jessica J. Lin served as the unpaid Guest Editors for the series. JJL serves as the unpaid Associate Editor-in-Chief of Translational Lung Cancer Research from October 2023 to September 2025.